Fig. 5From: A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA studySerum concentrations of infliximab (mean ± SD) versus time in the CT-P13 and RP treatment groups in the pharmacokinetic population. RP reference product (i.e., reference infliximab), SD standard deviationBack to article page